Fred Aslan, Artiva Biotherapeutics CEO

Arti­va re­files for IPO three years af­ter orig­i­nal plans in a vast­ly dif­fer­ent en­vi­ron­ment

Arti­va Bio­ther­a­peu­tics, a clin­i­cal-stage NK cell ther­a­py biotech, is try­ing again for the pub­lic mar­kets, it re­vealed Fri­day af­ter­noon in an SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.